Cytokinetics, Incorporated Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – CYTK

Cytokinetics, Incorporated Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – CYTK GlobeNewswire November 14, 2025 LOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) — The DJS Law Group reminds investors of a class action lawsuit against Cytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) for violations of §§10(b) […]

Canadian Investment Regulatory Organization Trade Resumption – COSA

Trading resumes in: Company: Cosa Resources Corp. TSX-Venture Symbol: COSA All Issues: Yes Resumption (ET): 8:00 AM CIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. CIRO is the national self-regulatory organization which

Halper Sadeh LLC Encourages MRSN, THS, HBAN Shareholders to Contact the Firm to Discuss Their Rights

(NASDAQ:MRSN),(NYSE:THS),(NASDAQ:HBAN), NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Mersana Therapeutics, Inc. (NASDAQ: MRSN)'s sale to Day One Biopharmaceuticals, Inc. Under the terms of the

Roadzen Reports $13.7 Million Second Quarter Revenue, a 15.2% Improvement Over Prior Year Quarter, and Fifth Consecutive Quarter of Adjusted EBITDA Improvement

(NasdaqGM:RDZN), Improving Fiscal Q2 and Record Six-Month RevenueRevenue increased 25.9% quarter-over-quarter and 15.2% year-over-year to $13.7 million; six-month revenue rose 18.0% to $24.5 million, reporting a record first half and best quarter in the last 12 months. Sharply Reduced Net Loss and Fifth Straight Quarter of Adjusted EBITDA1 ImprovementQ2 net loss narrowed to $(2.1) million

CPI Aerostructures Reports Third Quarter and Nine Month 2025 Results

(NYSE MKT:CVU), Third Quarter 2025 vs. Third Quarter 2024 Revenue of $19.3 million compared to $19.4 million; Gross profit of $4.3 million compared to $4.2 million; Gross margin of 22.3% compared to 21.7%; Net income of $1.1 million compared to net income of $0.7 million; Earnings per share of $0.09 compared to earnings per share

Wrap and K-Form Strengthen Made in America Supply Chain for Wrap’s Non-Lethal Response and CUAS Manufacturing

(NASDAQ:WRAP), MIAMI, Nov. 14, 2025 (GLOBE NEWSWIRE) — Wrap Technologies, Inc. (NASDAQ: WRAP) (“WRAP” or, the “Company”), a global leader in non-lethal response and public-safety technology solutions today announced a strategic partnership with K-Form Inc. (“K-Form”), a U.S.-based manufacturing and technology engineering firm, to help expand Wrap's supply chain and support scalable production of its

IES Holdings Announces Fiscal 2025 Fourth Quarter and Year-End Results Earnings Release Schedule

(NasdaqGM:IESC), HOUSTON, Nov. 14, 2025 (GLOBE NEWSWIRE) — IES Holdings, Inc. (or “IES” or the “Company”) (NASDAQ: IESC) today announced that it will release fiscal 2025 fourth quarter and year-end results before the market opens on Friday, November 21, 2025. About IES Holdings, Inc. IES designs and installs integrated electrical and technology systems and provides

SPAR Group, Inc. Appoints William Linnane as Permanent Chief Executive Officer

(NASDAQ:SGRP), CHARLOTTE, N.C., Nov. 14, 2025 (GLOBE NEWSWIRE) — (NASDAQ: SGRP) (“SPAR,” “SPAR Group” or the “Company”), an innovative services company offering comprehensive merchandising, marketing, and distribution solutions to retailers and brands throughout the United States and Canada, today announced the appointment of William Linnane as its Chief Executive Officer. Linnane, who has served as

Securities Fraud Class Action Filed Against Cytokinetics, Incorporated (CYTK) – Levi & Korsinsky Reminds Investors of November 17, 2025

NEW YORK, NY / ACCESS Newswire / November 14, 2025 / If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ:CYTK) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/cytokinetics-incorporated-lawsuit-submission-form-2?prid=177360&wire=1&utm_campaign=27 or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call

Scroll to Top